Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
HOTH
HOTH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HOTH News
Hoth Therapeutics Advances GDNF for Metabolic Dysfunction
13h ago
PRnewswire
Hoth Therapeutics Integrates AI for IND Preparation and Phase 1 Progression
6d ago
PRnewswire
Hoth Therapeutics Integrates AI to Support Rare Cancer Therapy Progression
6d ago
Newsfilter
Hoth Therapeutics Utilizes OpenAI API to Enhance Progress of Orphan HT-KIT Oncology Initiative
6d ago
moomoo
Hoth Therapeutics Deploys OpenAI API to Support HT-KIT Development
6d ago
Benzinga
Hoth Therapeutics Expands CLEER-001 Clinical Trial Amid Rising Patient Demand
Feb 24 2026
PRnewswire
Hoth Secures Patent to Enhance Immunology IP Portfolio
Feb 12 2026
PRnewswire
Hoth Therapeutics' GDNF Study Outperforms Semaglutide in Key Metrics
Feb 10 2026
stocktwits
Hoth Therapeutics' GDNF Therapy Shows Breakthrough Efficacy in Obesity Treatment
Feb 10 2026
PRnewswire
Hoth Therapeutics' GDNF Therapy Outperforms Semaglutide in Preclinical Study
Feb 10 2026
Newsfilter
Hoth Therapeutics Reveals GDNF Study Data for Obesity Treatment
Feb 10 2026
Benzinga
Hoth Therapeutics Reports Significant Clinical Results from HT-001 Trial in Cancer Patients
Jan 22 2026
Benzinga
Hoth Therapeutics Reports 50% Improvement in Cancer Patients with HT-001 in CLEER-001 Trial
Jan 22 2026
PRnewswire
Hoth Therapeutics Reports Significant Improvement in Cancer Patients' Condition in Clinical Trial
Jan 22 2026
Newsfilter
Hoth Therapeutics Secures China Patent for HT-KIT, Enhancing Oncology Market Protection
Jan 21 2026
PRnewswire
Hoth Therapeutics Secures China Patent for HT-KIT, Enhancing Oncology Market Protection
Jan 21 2026
Newsfilter
Show More News
